Roche-backed Dicerna pushes into the pack racing toward the blockbuster hep B goal line, armed with PhI data
Dicerna has lined up a set of proof-of-concept data from a small cohort of hepatitis B patients in a match-up against some heavyweight rivals which got out in front of this race. And right in the front row you’ll find a team from Roche, which paid $200 million in cash and offered another $1.5 billion in milestones to partner with Dicerna $DRNA on their RNAi program for hep B.
Right now it’s looking competitive, with lots of big challenges ahead.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.